Moderate Hepatic Impairment clinical trials

Explore recruiting moderate hepatic impairment clinical trials.

Recruiting moderate hepatic impairment studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Moderate Hepatic Impairment trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized Phase 2, open-label study of mirvetuximab soravtansine in patients with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression testing 2 schedules of administration for dose optimization, with a separate cohort to determine starting dose in patients with moderate hepatic impairment

Belgium, Poland, France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I study to evaluate the pharmacokinetics, safety, and tolerability of multiple oral doses of obefazimod in patients with mild and moderate hepatic impairment, compared to matched control groups.

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1, Open-label, Pharmacokinetic Study of TVB-2640 in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Function.

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Phase 1, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics Of Mavodelpar In Subjects With Impaired Hepatic Function

Hungary

Human Pharmacology (Phase I)- Other EU CTIS Study details

Moderate Hepatic Impairment trials by city

Moderate Hepatic Impairment in Toronto Moderate Hepatic Impairment in Vancouver Moderate Hepatic Impairment in Montreal Moderate Hepatic Impairment in Calgary Moderate Hepatic Impairment in Edmonton Moderate Hepatic Impairment in Ottawa Moderate Hepatic Impairment in Winnipeg Moderate Hepatic Impairment in Quebec City Moderate Hepatic Impairment in Hamilton Moderate Hepatic Impairment in Kitchener Moderate Hepatic Impairment in London Moderate Hepatic Impairment in Halifax Moderate Hepatic Impairment in New York Moderate Hepatic Impairment in Los Angeles Moderate Hepatic Impairment in Chicago Moderate Hepatic Impairment in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease